Molecular imaging is already engrained in early-stage trials for central nervous system disorders, but used infrequently in other therapeutic areas. What will it take to make it standard practice across the pipeline?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Molecular imaging as a de-risking tool: coming into focus?. Nat Rev Drug Discov 12, 251–252 (2013). https://doi.org/10.1038/nrd3993
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3993
